Observational study of healthcare workers' immunity to COVID-19

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The EuCARE-HCW study is an observational multicentre project that collects both retrospective and prospective data from healthcare workers who have either been vaccinated against COVID-19 or have had a confirmed SARS-CoV-2 infection. Participants will provide biological samples periodically over 12-24 months to analyze the impact of different viral variants on immunity. The study aims to understand the duration and breadth of immunity following vaccination and natural infection, as well as the potential for vaccine escape by various SARS-CoV-2 variants. This research involves collaboration across eight countries, enhancing the diversity of data collected.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The study subjects will be selected based on the following inclusion criteria:

1. Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
3. Having a signed informed consent when required by ethical approval

Exclusion Criteria: NONE

Where it's running

• Heinrich Heine university
  Düsseldorf, Germany Recruiting
• Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo
  Milan, Italy Recruiting
• Ieo Istituto Europeo Di Oncologia
  Milan, Italy Recruiting
• Viesoji Istaiga Vilniaus Uiversiteto Ligoninė Santaros klinikos
  Vilnius, Lithuania Recruiting
• Hospital Juan Ghaham Casasus
  Villahermosa, Mexico Recruiting
• Centro Hospitalar de Lisboa Ocidental
  Lisbon, Portugal Recruiting

Study contacts

• Study coordinator: Francesca Incardona, Dr
• Email: francesca.incardona@euresist.org
• Phone: +393356112830

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.